Wedbush Morgan upgrades Edwards Lifesciences (NYSE: EW) from Underperform to Neutral. Price target increased by $1 to $64.

Wedbush analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE